Trial Profile

Phase I/II multi-center open-label safety study of ATX101 in Japan

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupivacaine (Primary)
Indications Postoperative pain
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Feb 2025 New trial record
18 Feb 2025 According to Allay Therapeutics media release, Allay Therapeutics Japanese partner Maruishi Pharmaceutical has also dosed the first patient in January in a Phase I/II multi-center open-label safety study of ATX101 in Japan. Initial clinical data is expected to be shared in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com